Public interest has recently turned to the human eye and the Pfizer COVID-19 Vaccine. Two peer-reviewed papers have helped ...

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and ...

A new method of taking microscopic images of a live mouse's retina through the eye allows researchers to record the reaction of brain cells to disease and treatment. The Kobe University development is ...

The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial. During the 2025 congress of the European Society ...

Optain's portable robotic camera captures retinal images that help detect early-stage eye diseases, including diabetic retinopathy, glaucoma and age-related macular degeneration. It can also assess ...

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 ...

ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data ...

A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...

Semaglutide showed no significant association with increased risk of eye disorders or diabetic retinopathy in the meta-analysis. A potential link between semaglutide and increased risk of NAION was ...

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that can affect the ocular system, with retinal vasculitis and optic neuritis being rare but serious manifestations. We present a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 2 ACUITY trial met its primary safety endpoint ...